Showing results (491-500 of 592) with videos related to
Sort By:
Pageof 60
Journal of Personalized Medicine|August 29, 2024
Outcomes of Radiotherapy in Oligoprogressive Breast CancerFabio Marazzi, Valeria Masiello, Armando Orlandi, et al.Journal of Personalized Medicine|December 23, 2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient SeriesArmando Orlandi, Elena Iattoni, Laura Pizzuti, et al.Cancer Immunology, Immunotherapy : CII|September 5, 2023
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)Emanuele Vita, Alessio Stefani, Geny Piro, et al.Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective studyElisa Gobbini, Domenico Galetta, Marcello Tiseo, et al.Clinical Lung Cancer|July 30, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study ResultsFloriana Morgillo, Ester Del Signore, Emilio Bria, et al.Journal for Immunotherapy of Cancer|November 28, 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, et al.Journal of Translational Medicine|November 23, 2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancerAntonio Agostini, Ilaria Guerriero, Geny Piro, et al.Therapeutic Advances in Medical Oncology|October 2, 2024
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysisIgor Gomez-Randulfe, Sofía Silva Díaz, Carles Escriu, et al.ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.International Journal of Molecular Sciences|July 29, 2025
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic CombinationsItalia Falcone, Elena Giontella, Stefano Giuliani, et al.Pageof 60